Open Access
REVIEW
A double-edged sword: The HBV-induced non-coding RNAs alterations in hepatocellular carcinoma
TIANXING LIU1, HONGYAN DIAO2,*
1 Department of Cell and Systems Biology, University of Toronto, Toronto, Ontario, M5S1A1, Canada
2 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation
Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310003, China
* Corresponding Author: Hongyan Diao,
BIOCELL 2023, 47(1), 27-32. https://doi.org/10.32604/biocell.2022.023568
Received 03 May 2022; Accepted 12 July 2022; Issue published 26 September 2022
Abstract
Non-coding RNAs are speculated to exert important regulatory functions at the level of gene expression,
oncogenesis, and many other pathologies. Hepatitis B virus (HBV) infection is a leading cause of hepatocellular
carcinoma (HCC), and some studies have shown that the expression of non-coding RNAs has an assignable effect on
the development of HBV-induced HCC. In this context, the functions and molecular mechanisms of the HBVinduced non-coding RNA expression in the development of hepatoma have attracted increasing attention. This review
covers the progress in the exploration of the relationship between HBV-induced hepatoma and non-coding RNA
expression, cataloging the recent reports about the roles of non-coding RNAs in HBV-induced hepatoma into five
classes, including (1) modulation of metabolism in hepatic cancer, (2) aggravation of inflammation and hepatic
fibrosis, (3) alteration of the tumor immune microenvironment, (4) non-coding RNA N6-methyladenosine
modification, and a seemingly opposite process, (5) the suppression of the progression of HBV-related HCC. All
evidence supports non-coding RNAs as promising novel targets for the early diagnosis and treatments for HCC.
Keywords
Cite This Article
LIU, T., DIAO, H. (2023). A double-edged sword: The HBV-induced non-coding RNAs alterations in hepatocellular carcinoma.
BIOCELL, 47(1), 27–32.